Infinity Pharma (INFI) & Bristol-Myers Squibb Report Expansion of Clinical Collaboration Evaluating IPI-549 in Combination with Opdivo (Nivolumab)
Tweet Send to a Friend
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has expanded its existing clinical collaboration with Bristol-Myers Squibb (NYSE: BMY) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
